$DARE
Dare Bioscience, Inc.

2015 Q1 Form 10-K Financial Statement

#000156459015001834 Filed on March 19, 2015

View on sec.gov

Income Statement

Concept 2015 Q1 2014 2013 Q4
Revenue $0.00 $80.00K $6.000K
YoY Change -100.0% 1233.33%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.680M $8.590M $1.580M
YoY Change 77.48% 39.22% 37.39%
% of Gross Profit
Research & Development $5.021M $11.77M $1.440M
YoY Change 235.85% 21.36% -64.36%
% of Gross Profit
Depreciation & Amortization $41.00K $126.0K $40.00K
YoY Change 13.89% -36.04% -50.0%
% of Gross Profit
Operating Expenses $7.702M $20.36M $3.015M
YoY Change 156.31% 28.32% -41.91%
Operating Profit
YoY Change
Interest Expense $721.0K -$1.070M $430.0K
YoY Change 56.4% -171.96% -253.57%
% of Operating Profit
Other Income/Expense, Net -$718.0K -$3.063M -$471.0K
YoY Change -1731.82% 138.74% -4810.0%
Pretax Income -$8.430M -$23.34M -$3.480M
YoY Change 189.69% 36.17% -36.15%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$8.420M -$23.34M -$3.480M
YoY Change 188.95% 36.16% -36.15%
Net Earnings / Revenue -29177.5% -58000.0%
Basic Earnings Per Share
Diluted Earnings Per Share -$4.132M -$16.10M -$2.434M
COMMON SHARES
Basic Shares Outstanding 20.38M
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q1 2014 2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $56.32M $51.17M $5.490M
YoY Change 564.94% 832.06% -67.15%
Cash & Equivalents $56.32M $51.17M $5.488M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables $2.270M $1.660M $960.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $58.58M $52.84M $6.447M
YoY Change 409.36% 719.22% -62.21%
LONG-TERM ASSETS
Property, Plant & Equipment $330.0K $340.0K $245.0K
YoY Change 47.98% 36.0% -44.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $469.0K $220.0K $135.0K
YoY Change 260.77% 57.14% -15.63%
Total Long-Term Assets $799.0K $550.0K $380.0K
YoY Change 126.35% 44.74% -36.67%
TOTAL ASSETS
Total Short-Term Assets $58.58M $52.84M $6.447M
Total Long-Term Assets $799.0K $550.0K $380.0K
Total Assets $59.38M $53.39M $6.827M
YoY Change 400.94% 681.7% -61.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.682M $1.260M $914.0K
YoY Change -22.13% 38.46% 1.56%
Accrued Expenses $2.736M $3.650M $2.274M
YoY Change 83.26% 60.79% -17.01%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $8.820M
YoY Change -100.0% -100.0%
Long-Term Debt Due $840.0K $3.120M $3.130M
YoY Change -73.75% -0.32% 9.06%
Total Short-Term Liabilities $5.289M $8.060M $15.15M
YoY Change -78.13% -46.8% 132.3%
LONG-TERM LIABILITIES
Long-Term Debt $13.58M $0.00 $3.120M
YoY Change 490.43% -100.0% -50.16%
Other Long-Term Liabilities $110.0K $10.00K $12.00K
YoY Change 685.71% -99.25% -98.97%
Total Long-Term Liabilities $13.68M $10.00K $4.455M
YoY Change 329.37% -99.78% -40.04%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.289M $8.060M $15.15M
Total Long-Term Liabilities $13.68M $10.00K $4.455M
Total Liabilities $18.97M $8.070M $19.60M
YoY Change -30.67% -58.83% 40.51%
SHAREHOLDERS EQUITY
Retained Earnings -$130.2M -$98.44M
YoY Change
Common Stock $170.6M $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $40.41M $45.33M -$94.30M
YoY Change
Total Liabilities & Shareholders Equity $59.38M $53.39M $6.827M
YoY Change 400.94% 681.7% -61.34%

Cashflow Statement

Concept 2015 Q1 2014 2013 Q4
OPERATING ACTIVITIES
Net Income -$8.420M -$23.34M -$3.480M
YoY Change 188.95% 36.16% -36.15%
Depreciation, Depletion And Amortization $41.00K $126.0K $40.00K
YoY Change 13.89% -36.04% -50.0%
Cash From Operating Activities -$7.940M -$19.06M -$3.270M
YoY Change 116.35% 14.75% -35.12%
INVESTING ACTIVITIES
Capital Expenditures $29.00K $225.0K $0.00
YoY Change 107.14% 3114.29% -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $40.00K $0.00
YoY Change -100.0%
Cash From Investing Activities -$30.00K -$190.0K $0.00
YoY Change 1800.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.411M $140.0K
YoY Change 8829.63% 300.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 13.11M 64.93M -1.150M
YoY Change 97.14% 1102.41% -109.06%
NET CHANGE
Cash From Operating Activities -7.940M -19.06M -3.270M
Cash From Investing Activities -30.00K -190.0K 0.000
Cash From Financing Activities 13.11M 64.93M -1.150M
Net Change In Cash 5.140M 45.68M -4.420M
YoY Change 72.48% -507.13% -158.39%
FREE CASH FLOW
Cash From Operating Activities -$7.940M -$19.06M -$3.270M
Capital Expenditures $29.00K $225.0K $0.00
Free Cash Flow -$7.969M -$19.29M -$3.270M
YoY Change 116.31% 16.06% -34.07%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014 dei Document Period End Date
DocumentPeriodEndDate
2014-12-31
CY2014 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q4 us-gaap Assets Current
AssetsCurrent
52836000
CY2014 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014Q4 us-gaap Assets
Assets
53393000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
215000
CY2014 dei Document Type
DocumentType
10-K
CY2013Q4 us-gaap Assets Current
AssetsCurrent
6447000
CY2014 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2014 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2014 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2014 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2015Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20375987
CY2014Q2 dei Entity Public Float
EntityPublicFloat
74209799.40
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51174000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5488000
CY2013Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
8824000
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
34000
CY2013Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
928000
CY2013Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
391000
CY2013Q4 us-gaap Temporary Equity Value Excluding Additional Paid In Capital
TemporaryEquityValueExcludingAdditionalPaidInCapital
81525000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
167104000
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4140000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-98439000
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2014 dei Entity Registrant Name
EntityRegistrantName
CERULEAN PHARMA INC.
CY2014Q4 ceru Accounts Receivable Prepaid Expense And Other Current Assets
AccountsReceivablePrepaidExpenseAndOtherCurrentAssets
1662000
CY2014 dei Trading Symbol
TradingSymbol
CERU
CY2014 dei Entity Central Index Key
EntityCentralIndexKey
0001401914
CY2014 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
342000
CY2014Q4 us-gaap Loans Payable Current
LoansPayableCurrent
3124000
CY2014 dei Amendment Flag
AmendmentFlag
false
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
245000
CY2013Q4 us-gaap Assets
Assets
6827000
CY2013Q4 us-gaap Loans Payable Current
LoansPayableCurrent
3134000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1255000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
914000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3648000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8061000
CY2013Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
3124000
CY2013Q4 ceru Accounts Receivable Prepaid Expense And Other Current Assets
AccountsReceivablePrepaidExpenseAndOtherCurrentAssets
959000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
135000
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2274000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15146000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7000
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
12000
CY2014Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
7000
CY2013Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4455000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-121781000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-23342000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-17143000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
45325000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-94299000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
53393000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6827000
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.60
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14548516
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
684330
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11772000
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9700000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8587000
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
785531
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20125049
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20125049
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
785531
CY2014 us-gaap Revenues
Revenues
80000
CY2013 us-gaap Revenues
Revenues
6000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6166000
CY2014 us-gaap Operating Expenses
OperatingExpenses
20359000
CY2013 us-gaap Operating Expenses
OperatingExpenses
15866000
CY2014 us-gaap Investment Income Interest
InvestmentIncomeInterest
9000
CY2013 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
CY2013 us-gaap Interest Expense
InterestExpense
1487000
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
140000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
885000
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-7000
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
35000
CY2014 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3348000
CY2012 us-gaap Interest Expense
InterestExpense
567000
CY2014 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2493000
CY2014 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-504000
CY2013 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-202000
CY2012 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-39000
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3063000
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1283000
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-526000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-22101000
CY2012 us-gaap Revenues
Revenues
625000
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15807000
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6393000
CY2012 us-gaap Operating Expenses
OperatingExpenses
22200000
CY2012 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
CY2012 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
3000
CY2012 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
73000
CY2013 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3084000
CY2013 ceru Increase Decrease Accounts Receivable Prepaid Expenses And Other Current Assets
IncreaseDecreaseAccountsReceivablePrepaidExpensesAndOtherCurrentAssets
229000
CY2014 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23342000
CY2013 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17143000
CY2012 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22174000
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-25.05
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-36.39
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
609344
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
-58397000
CY2012 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
529000
CY2012 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
-73000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-80039000
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
35000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
622000
CY2013 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
2226000
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
59862000
CY2014 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
81526000
CY2014 ceru Conversion Of Convertible Notes
ConversionOfConvertibleNotes
20129000
CY2014 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
187000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
885000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
622000
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
529000
CY2014 us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
29000
CY2013 us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
-1000
CY2012 us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
-68000
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
126000
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
197000
CY2012 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
346000
CY2014 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
28000
CY2013 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-7000
CY2012 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2000
CY2014 us-gaap Paid In Kind Interest
PaidInKindInterest
416000
CY2013 us-gaap Paid In Kind Interest
PaidInKindInterest
588000
CY2012 us-gaap Paid In Kind Interest
PaidInKindInterest
61000
CY2014 ceru Increase Decrease Accounts Receivable Prepaid Expenses And Other Current Assets
IncreaseDecreaseAccountsReceivablePrepaidExpensesAndOtherCurrentAssets
713000
CY2012 ceru Increase Decrease Accounts Receivable Prepaid Expenses And Other Current Assets
IncreaseDecreaseAccountsReceivablePrepaidExpensesAndOtherCurrentAssets
61000
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
341000
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
14000
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-163000
CY2014 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1236000
CY2013 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-467000
CY2012 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
489000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-19061000
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-16614000
CY2012 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-21005000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
225000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
180000
CY2014 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
40000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-185000
CY2012 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-180000
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
140000
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3000
CY2014 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
8500000
CY2013 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
8824000
CY2014 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
59862000
CY2012 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
10000000
CY2013 us-gaap Interest Paid Net
InterestPaidNet
664000
CY2012 ceru Fair Value Adjustment Of Preferred Stock Warrants
FairValueAdjustmentOfPreferredStockWarrants
360000
CY2014 us-gaap Interest Paid Net
InterestPaidNet
400000
CY2012 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
376000
CY2014 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
222000
CY2013 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
373000
CY2012 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
4000
CY2012 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
12927000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
64932000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5402000
CY2012 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
22547000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
45686000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-11219000
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1362000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16707000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15345000
CY2014 us-gaap Convertible Preferred Stock Converted To Other Securities
ConvertiblePreferredStockConvertedToOtherSecurities
81526000
CY2013 us-gaap Convertible Preferred Stock Converted To Other Securities
ConvertiblePreferredStockConvertedToOtherSecurities
2226000
CY2014 ceru Conversion Of Accrued Interest And Convertible Notes Payable
ConversionOfAccruedInterestAndConvertibleNotesPayable
20129000
CY2014 ceru Reclassification Of Warrants Adjusted In Additional Paid In Capital
ReclassificationOfWarrantsAdjustedInAdditionalPaidInCapital
424000
CY2012 us-gaap Interest Paid Net
InterestPaidNet
507000
CY2014 us-gaap Nature Of Operations
NatureOfOperations
<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:bold;">1.</p></td> <td valign="top" style="width:95.46%;"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NATURE OF BUSINESS AND OPERATIONS </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Nature of Business<font style="font-weight:normal;"> &#8212; Cerulean Pharma Inc. (the &#8220;Company&#8221;) was incorporated on November&#160;28, 2005, as a Delaware corporation and is located in Cambridge, Massachusetts. The Company was formed to develop novel, nanotechnology-based therapeutics in the areas of oncology and other diseases. In 2013, the Company formed a wholly-owned subsidiary, Cerulean Pharma Australia Pty&#160;Ltd as an Australian-based proprietary limited company, to perform clinical activities in Australia. To date, operations of the Australia subsidiary have been immaterial. </font></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's operations to date have consisted primarily of raising capital, product research and development, and initial market development. Accordingly, the Company is considered to be in the development stage at December 31, 2014. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has not generated any revenue related to its primary business purpose to date and is subject to a number of risks similar to those of other development stage life science companies, including dependence on key individuals, competition from other companies, the need for development of commercially viable products, and the need to obtain adequate additional financing to fund the development of its product candidates. The Company is also subject to a number of risks similar to other companies in the industry, including rapid technological change, regulatory approval of products, uncertainty of market acceptance of products, competition from substitute products and larger companies, the need to obtain additional financing, compliance with government regulations, protection of proprietary technology, dependence on third parties, product liability and dependence on key individuals.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has an accumulated deficit of $121.8 million at December 31, 2014. The Company has financed its operations primarily through private placements of its preferred stock, proceeds from borrowings, and an initial public offering completed in 2014. The Company has not completed development of any product candidate and has devoted substantially all of its financial resources and efforts to research and development, including preclinical and clinical development. The Company expects to continue to incur significant expenses and increasing operating losses for at least several years.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Initial Public Offering<font style="font-weight:normal;"> &#8212; On April 15, 2014, the Company completed the sale of 8,500,000 shares of its common stock in its initial public offering (the &#8220;IPO&#8221;), at a price to the public of $7.00 per share. On May 7, 2014, the Company completed the sale of an additional 1,069,715 shares of common stock at a price to the public of $7.00 per share under a partial exercise by the underwriters of their option to purchase additional shares of common stock. The sale of shares to the public resulted in net proceeds of $59.9 million after deducting underwriting discounts and commissions and offering expenses payable by the Company. </font></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In preparation for the IPO, the Company&#8217;s board of directors and stockholders approved a 1-for-14.5074 reverse stock split of the Company&#8217;s common stock effective March 31, 2014. All share and per share amounts in the consolidated financial statements contained herein and notes thereto have been retroactively adjusted, where necessary, to give effect to this reverse stock split. In connection with the closing of the IPO, all of the Company&#8217;s outstanding redeemable convertible preferred stock and convertible notes automatically converted into shares of common stock as of April 15, 2014, resulting in the issuance by the Company of an additional 9,728,237 shares of common stock. The significant increase in shares outstanding in April 2014 is expected to impact the year-over-year comparability of the Company&#8217;s net loss per share calculations in future periods. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the completion of the IPO on April 15, 2014, the Company&#8217;s outstanding warrants to purchase 1,857,226 shares of the Company&#8217;s preferred stock automatically converted into warrants to purchase an aggregate of 128,663 shares of the Company&#8217;s common stock and, as a result, the Company reclassified the warrant liability to additional paid-in capital.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
CY2014 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Use of Estimates<font style="font-weight:normal;"> &#8212; </font><font style="color:#;font-weight:normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</font></p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On an ongoing basis, the Company's management evaluates its estimates, including estimates related to clinical trial accruals, stock-based compensation expense, and reported amounts of revenues and expenses during the reported period. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</p></div>
CY2014 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Concentrations of Credit Risk<font style="font-weight:normal;"> &#8212; Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. Substantially all of the Company&#8217;s cash and cash equivalents are </font><font style="font-weight:normal;">held at one financial institution that management believes to be of high-credit quality. Deposits with this financial institution may exceed the amount of insurance provided on such deposits; however these deposits may be redeemed upon demand and, therefore, bear minimal risk. </font></p></div>
CY2014 us-gaap Derivatives Reporting Of Derivative Activity
DerivativesReportingOfDerivativeActivity
<div> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Preferred Stock Warrant Liability<font style="font-weight:normal;"> &#8212; Freestanding warrants related to shares that are redeemable or contingently redeemable are classified as a liability on the Company&#8217;s balance sheets. The Company uses the Black-Scholes option-pricing model to estimate the fair value of the warrants. Changes in the fair value of these warrants are recorded in the statements of operations. </font><font style="font-weight:normal;">All of the Company&#8217;s warrants to purchase preferred stock were converted to warrants to purchase common stock upon the Company&#8217;s IPO in April 2014.&nbsp;&nbsp;Accordingly, the preferred stock warrant liability was reclassified to additional paid-in capital. </font></p></div>
CY2014 us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<div> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Guarantees and Indemnification<font style="font-weight:normal;"> &#8212;&#160;As permitted under Delaware law, the Company indemnifies its officers, directors, and employees for certain events or occurrences while the officer or director is, or was serving at the Company&#8217;s request in such a capacity.&#160;The term of the indemnification is for the officer&#8217;s or director&#8217;s lifetime. </font></p></div>
CY2014 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2005-11-28
CY2014Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
14.5074
CY2014 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
117000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
117000
CY2014 ceru Lease Expiration Period Month And Year
LeaseExpirationPeriodMonthAndYear
2016-02
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1777000
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1532000
CY2014Q4 ceru Accrued Expenses Current
AccruedExpensesCurrent
663000
CY2013Q4 ceru Accrued Expenses Current
AccruedExpensesCurrent
379000
CY2014Q4 ceru Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
848000
CY2013Q4 ceru Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
610000
CY2014Q4 ceru Accrued Manufacturing Expenses Current
AccruedManufacturingExpensesCurrent
580000
CY2013Q4 ceru Accrued Manufacturing Expenses Current
AccruedManufacturingExpensesCurrent
433000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
983000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
618000
CY2014Q4 ceru Debt Instrument Accrued Interest
DebtInstrumentAccruedInterest
574000
CY2013Q4 ceru Debt Instrument Accrued Interest
DebtInstrumentAccruedInterest
234000
CY2013Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
8824000
CY2013Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.07
CY2014Q1 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.07
CY2014Q2 us-gaap Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger
DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
0.775
CY2014 us-gaap Initial Offering Period
InitialOfferingPeriod
2014-04-15
CY2014Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2493000
CY2014Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
3321000
CY2014Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
197000
CY2014Q4 us-gaap Loans Payable
LoansPayable
3124000
CY2014Q2 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
6826004
CY2013Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
88894772
CY2013Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
85207356
CY2013Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
85207356
CY2013Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
81990000
CY2014 ceru Stock Issued During Period Shares New Issues Conversion Securities And Options Exercised
StockIssuedDuringPeriodSharesNewIssuesConversionSecuritiesAndOptionsExercised
19297952
CY2014Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3689767
CY2013Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8156461
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1062694
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1138170
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
41566
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
33122
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2126176
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
859690
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
786623
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.98
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.99
CY2014Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
50541000
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.36
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.85
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.97
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.46
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.41
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M12D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y2M12D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y10M24D
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7028
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2701
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1105
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1541
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
885000
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
622000
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
529000
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0171
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0109
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0083
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0200
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0192
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0112
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.54
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.59
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.77
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.60
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.79
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.79
CY2013Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
5233000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
29442
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
25696
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1715
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1525
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
3503
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
3067
CY2014Q4 ceru Deferred Tax Assets Capitalized Research And Development Cost
DeferredTaxAssetsCapitalizedResearchAndDevelopmentCost
9938
CY2013Q4 ceru Deferred Tax Assets Capitalized Research And Development Cost
DeferredTaxAssetsCapitalizedResearchAndDevelopmentCost
6992
CY2014Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
422
CY2013Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
220
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
45020
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
37500
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
45020
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
37500
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7600000
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7100000
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.045
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.050
CY2014 ceru Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.037
CY2014Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
41000
CY2013Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
12000
CY2014 ceru Lease Commencement Date
LeaseCommencementDate
2014-07-15
CY2014 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
766000
CY2013 ceru Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.002
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.008
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
598000
CY2012 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
517000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
954000
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.014
CY2014 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.009
CY2013 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.011
CY2014 ceru Effective Income Tax Rate Reconciliation Expiration Of State Net Operating Loss
EffectiveIncomeTaxRateReconciliationExpirationOfStateNetOperatingLoss
-0.017
CY2013 ceru Effective Income Tax Rate Reconciliation Expiration Of State Net Operating Loss
EffectiveIncomeTaxRateReconciliationExpirationOfStateNetOperatingLoss
-0.042
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
160000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1114000
CY2014 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
39000
CY2014Q2 us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
30000
CY2015Q1 us-gaap Debt Instrument Interest Rate Terms
DebtInstrumentInterestRateTerms
The Term Loan will mature on July 1, 2018. Each advance under the Term Loan accrues interest at a floating per annum rate equal to the greater of (i) 7.30% or (ii) the sum of 7.30% plus the prime rate minus 5.75%. The Term Loan provides for interest-only payments on a monthly basis until December 31, 2015
CY2015Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
30000000
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.008
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.002
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.322
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.355
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2014 ceru Operating Loss Carry Forwards Expiration Period
OperatingLossCarryForwardsExpirationPeriod
2034
CY2014 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2013-02-28
CY2014 us-gaap Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
P3Y
CY2014 us-gaap Long Term Debt Maturities Repayment Terms
LongTermDebtMaturitiesRepaymentTerms
Any such prepayment of the Term Loan is subject to a prepayment charge of (i) 3.0% if such prepayment occurs within twelve months of the Closing Date, (ii) 2.0% if such prepayment occurs after twelve months following the Closing Date but on or prior to twenty-four months following the Closing Date, and (iii) 1.0% thereafter
CY2014 ceru Debt Instrument Additional Interest Rate Accrue On Default
DebtInstrumentAdditionalInterestRateAccrueOnDefault
0.050
CY2014 ceru Debt Instrument Interest Rate Of Final Payment On Principal Amount
DebtInstrumentInterestRateOfFinalPaymentOnPrincipalAmount
0.0670
CY2014Q1 us-gaap Revenues
Revenues
47000
CY2014Q2 us-gaap Revenues
Revenues
33000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1495000
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2648000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2928000
CY2014Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4701000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1510000
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2029000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2441000
CY2014Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2607000
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
3005000
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
4677000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
5369000
CY2014Q4 us-gaap Operating Expenses
OperatingExpenses
7308000
CY2014Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000
CY2014Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
CY2014Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
CY2014Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
4000
CY2014Q1 us-gaap Interest Expense
InterestExpense
461000
CY2014Q2 us-gaap Interest Expense
InterestExpense
268000
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3195000
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1586000
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
786986
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16883716
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20124574
CY2014Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20125009
CY2014Q3 us-gaap Interest Expense
InterestExpense
191000
CY2014Q4 us-gaap Interest Expense
InterestExpense
163000
CY2014Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2493000
CY2014Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-504000
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7403000
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5558000
CY2014Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7467000
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.70
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
CY2014Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
44000
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2759000
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-189000
CY2014Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-159000
CY2014Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2914000
CY2013Q4 us-gaap Revenues
Revenues
6000
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3479000
CY2013Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1440000
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1972000
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1392000
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1227000
CY2013Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1575000
CY2013Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-231000
CY2013Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-20000
CY2013Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
7000
CY2013Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
42000
CY2013Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-121000
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
5451000
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
4587000
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
2813000
CY2013Q4 us-gaap Operating Expenses
OperatingExpenses
3015000
CY2013Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000
CY2013Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000
CY2013Q1 us-gaap Interest Expense
InterestExpense
353000
CY2013Q2 us-gaap Interest Expense
InterestExpense
326000
CY2013Q3 us-gaap Interest Expense
InterestExpense
378000
CY2013Q4 us-gaap Interest Expense
InterestExpense
430000
CY2013Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-306000
CY2013Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-385000
CY2013Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-471000
CY2013Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5572000
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4893000
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3198000
CY2013Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3480000
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-9.09
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.96
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.40
CY2013Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.45
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
612836
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
614662
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
726987
CY2013Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
782335

Files In Submission

Name View Source Status
0001564590-15-001834-index-headers.html Edgar Link pending
0001564590-15-001834-index.html Edgar Link pending
0001564590-15-001834.txt Edgar Link pending
0001564590-15-001834-xbrl.zip Edgar Link pending
ceru-10k_20141231.htm Edgar Link pending
ceru-20141231.xml Edgar Link completed
ceru-20141231.xsd Edgar Link pending
ceru-20141231_cal.xml Edgar Link unprocessable
ceru-20141231_def.xml Edgar Link unprocessable
ceru-20141231_lab.xml Edgar Link unprocessable
ceru-20141231_pre.xml Edgar Link unprocessable
ceru-ex1028_20141231821.htm Edgar Link pending
ceru-ex1031_201412311454.htm Edgar Link pending
ceru-ex211_20141231823.htm Edgar Link pending
ceru-ex231_20141231988.htm Edgar Link pending
ceru-ex311_20141231824.htm Edgar Link pending
ceru-ex312_20141231825.htm Edgar Link pending
ceru-ex321_20141231826.htm Edgar Link pending
ceru-ex322_20141231827.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g201503191949481157259.jpg Edgar Link pending
g201503191949486787260.jpg Edgar Link pending
g201503191949486787261.jpg Edgar Link pending
g201503191949488187262.jpg Edgar Link pending
g201503191949488187263.jpg Edgar Link pending
g201503191949489287264.jpg Edgar Link pending
g201503191949490377265.jpg Edgar Link pending
g201503191949491627266.jpg Edgar Link pending
g201503191949491787267.jpg Edgar Link pending
g201503191949493967268.jpg Edgar Link pending
g201503191949494437269.jpg Edgar Link pending
g201503191949496787270.jpg Edgar Link pending
g201503191949497717271.jpg Edgar Link pending
g201503191949497877272.jpg Edgar Link pending
g201503191949501157273.jpg Edgar Link pending
g201503191949505377274.jpg Edgar Link pending
g201503191949505537275.jpg Edgar Link pending
g201503191949508507276.jpg Edgar Link pending
g201503191950033347277.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending